Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS

IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, is proud to announce that its inFoods® IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a Henry Schein publication. The article, titled “Precision Medicine for IBS: A Novel, IBS-Specific Immune Response Guided Dietary Therapy”, presents comprehensive clinical and scientific insights into the company’s innovative approach to managing Irritable Bowel Syndrome (IBS).

Read more at globenewswire.com